RT Journal Article
SR Electronic
T1 Imported SARS-COV-2 Variants of Concern Drove Spread of Infections Across Kenya During the Second Year of the Pandemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.28.22271467
DO 10.1101/2022.02.28.22271467
A1 Nasimiyu, Carolyne
A1 Matoke-Muhia, Damaris
A1 Rono, Gilbert K.
A1 Osoro, Eric
A1 Obado, Daniel O.
A1 Mwangi, J. Milkah
A1 Mwikwabe, Nicholas
A1 Thiong’o, Kelvin
A1 Dawa, Jeanette
A1 Ngere, Isaac
A1 Gachohi, John
A1 Kariuki, Samuel
A1 Amukoye, Evans
A1 Mureithi, Marianne
A1 Ngere, Philip
A1 Amoth, Patrick
A1 Were, Ian
A1 Makayotto, Lyndah
A1 Nene, Vishvanath
A1 Abworo, Edward O.
A1 Njenga, M. Kariuki
A1 Seifert, Stephanie N.
A1 Oyola, Samuel O.
YR 2022
UL http://medrxiv.org/content/early/2022/02/28/2022.02.28.22271467.abstract
AB Background Using classical and genomic epidemiology, we tracked the COVID-19 pandemic in Kenya over 23 months to determine the impact of SARS-CoV-2 variants on its progression.Methods SARS-CoV-2 surveillance and testing data were obtained from the Kenya Ministry of Health, collected daily from 306 health facilities. COVID-19-associated fatality data were also obtained from these health facilities and communities. Whole SARS-CoV-2 genome sequencing were carried out on 1241 specimens.Results Over the pandemic duration (March 2020 - January 2022) Kenya experienced five waves characterized by attack rates (AR) of between 65.4 and 137.6 per 100,000 persons, and intra-wave case fatality ratios (CFR) averaging 3.5%, two-fold higher than the national average COVID-19 associated CFR. The first two waves that occurred before emergence of global variants of concerns (VoC) had lower AR (65.4 and 118.2 per 100,000). Waves 3, 4, and 5 that occurred during the second year were each dominated by multiple introductions each, of Alpha (74.9% genomes), Delta (98.7%), and Omicron (87.8%) VoCs, respectively. During this phase, government-imposed restrictions failed to alleviate pandemic progression, resulting in higher attack rates spread across the country.Conclusions The emergence of Alpha, Delta, and Omicron variants was a turning point that resulted in widespread and higher SARS-CoV-2 infections across the country.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by US National Institute of Allergy and Infectious Disease/National Institutes of Health (NIAID/NIH), grants number U01AI151799 and U01AI151799-02S1 through the Centre for Research in Emerging Infectious Diseases-East and Central Africa (CREID-ECA). Funding was also provided by Research Program on Livestock of the Consultative Group for International Agricultural Research, Rockefeller Foundation, Africa-Centers for Disease Control and Prevention, Kenya Medical Research Institute Grant #KEMRI/COV/SPE/012. Carolyne Nasimiyu was supported by the Fogarty International Center and NIAID/NIH under grant number D43TW011519.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The COVID-19 surveillance and testing data was collected from public database of the Kenya Ministry of Health (KMOH) with administrative approval from the ministry. Genomic surveillance study was reviewed and approved by the KEMRI Scientific and Ethical Review Unit (KEMRI/SERU/CVR/006/4035), ILRI Institutional Research Ethics Committee (ILRI-IREC2020-52), and a reliance approval provided by Washington State University Institutional Review Board based on in-country ethical reviews as provided for in Code of Federal Regulations (45 C.F.R part 46 and 21 C.F.R. part 56).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at GISAID or NCBI or through the Kenya Ministry of Health.